Trials & Filings

J&J’s Invokana Approved in EU

SGLT2-inhibiting diabetes treatment was launched in U.S. last March

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Janssen-Cilag International NV, a division of Johnson & Johnson, received EC approval for Invokana (canagliflozin) in the EU for the treatment of adults with type 2 diabetes mellitus, to improve glycemic control. Canagliflozin is an oral, once-daily medication, performing as a sodium glucose co-transporter 2 (SGLT2) inhibitor. Canagliflozin is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycemic control, as monotherapy when diet and exercise alone do...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters